蛋白激酶B
癌症
生物
mTORC2型
AKT2型
RPTOR公司
肿瘤科
作者
Weikai Xiao,Guochun Zhang,Bo Chen,Xiaoqing Chen,Lingzhu Wen,Jianguo Lai,Xuerui Li,Min Li,Hao Liu,Jing L. Liu,Han Han‐Zhang,Analyn Lizaso,Ning Liao
出处
期刊:Journal of Cancer
[Ivyspring International Publisher]
日期:2021-01-01
卷期号:12 (14): 4408-4417
被引量:55
摘要
Background: Comprehensive analysis of PI3K-AKT-mTOR pathway gene alterations in breast cancer may be helpful for targeted therapy.Methods: We performed targeted sequencing using a panel of 520 cancer-related genes to investigate gene alterations in the PI3K-AKT-mTOR pathway from 589 consecutive Chinese women diagnosed with stage I-III breast cancer.Analyses of overall survival (OS) were performed using the publicly available clinical and genomic data from METABRIC.Results: PI3K-AKT-mTOR pathway gene alterations were detected in 62.6% (369/589) of our cohort.The most commonly altered genes were PIK3CA (45%), PTEN (7.5%), AKT1 (5.9 %), PIK3R1 (2.7%), and PIK3CG (2%).Four PIK3CA mutations (E545K, H1047R, E542K, and H1047L) were detected in all the breast cancer molecular subtypes.Seven PIK3CA mutations (E545G, E418_L422delinsV, E726K, E110del, G1049R, G118D, and D350G) were only detected in HR + subtypes.Two PIK3CA mutations (C420R and N345K) were only detected in non-triple-negative subtypes.Most cases with PTEN mutation were HR + /HER2 -subtype (77.3%), followed by triple-negative subtype (18.2%).In the METABRIC breast cancer dataset, no significant OS difference was observed between the PIK3CA-mutant and wild-type groups.However, patients with multiple PIK3CA mutations (mOS: 131 vs. 159 months, P= 0.029), or PIK3CA mutations located in the C2 domain had significantly shorter OS (mOS, 130 vs. 154 months, P=0.020) than those without the mutations.Conclusions: Our study reveals the heterogeneity in PI3K-AKT-mTOR pathway among the breast cancer molecular subtypes in our cohort.Moreover, the number and specific sites of PIK3CA mutations have distinct prognostic impact.
科研通智能强力驱动
Strongly Powered by AbleSci AI